Akeso CEO highlights significance of biliary tract cancer trial results
Akeso's CEO Michelle Xia discussed why the company's PD-1xVEGF bispecific ivonescimab data for biliary tract cancer are particularly noteworthy. She emphasized the potential impact of the therapy in a difficult-to-treat cancer type. The program has drawn intense industry attention as one of the most closely watched drug candidates.
Related stories
Study highlights industry's dominance in cancer research amid federal funding cuts · Cancer research
Upcoming readouts expected for experimental cardiovascular drug class · Drug development
Spyre halts RA program for anti-TL1A candidate after Phase 2 disappointment · Drug development
This summary is AI-generated and original to Mobble; the linked article is the authoritative source.
Original headline: “Q&A: Akeso CEO spells out why she thinks its biliary tract cancer data are a big deal.” Browse more stories.